Related references
Note: Only part of the references are listed.Serum uric acid, predicts heart failure in a large Italian cohort: search for a cut-off value the URic acid Right for heArt Health study
Maria L. Muiesan et al.
JOURNAL OF HYPERTENSION (2021)
Pegloticase in Combination With Methotrexate in Patients With Uncontrolled Gout: A Multicenter, Open-label Study (MIRROR)
John K. Botson et al.
JOURNAL OF RHEUMATOLOGY (2021)
Clinical Effects of Xanthine Oxidase Inhibitors in Hyperuricemic Patients
Arrigo F. G. Cicero et al.
MEDICAL PRINCIPLES AND PRACTICE (2021)
To switch or not switch febuxostat: comment on the article by FitzGerald et al
Chuanhui Xu
ARTHRITIS & RHEUMATOLOGY (2021)
Elevated serum uric acid is associated with a greater inflammatory response and with short- and long-term mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention
Alessandro Mandurino-Mirizzi et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2021)
Identification of the Uric Acid Thresholds Predicting an Increased Total and Cardiovascular Mortality Over 20 Years
Agostino Virdis et al.
HYPERTENSION (2020)
2020 American College of Rheumatology Guideline for the Management of Gout
John D. FitzGerald et al.
ARTHRITIS & RHEUMATOLOGY (2020)
Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial
Isla S. Mackenzie et al.
LANCET (2020)
Gout: state of the art after a decade of developments
Tristan Pascart et al.
RHEUMATOLOGY (2019)
Safety and tolerability of available urate-lowering drugs: a critical review
Larysa Strilchuk et al.
EXPERT OPINION ON DRUG SAFETY (2019)
Pegloticase Treatment Significantly Decreases Blood Pressure in Patients With Chronic Gout
Richard J. Johnson et al.
HYPERTENSION (2019)
The net clinical benefits of febuxostat versus allopurinol in patients with gout or asymptomatic hyperuricemia - A systematic review and meta-analysis
Cheng-Wei Liu et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2019)
Safety and efficacy of verinurad, a selective URAT1 inhibitor, for the treatment of patients with gout and/or asymptomatic hyperuricemia in the United States and Japan: Findings from two phase II trials
David Fitz-Patrick et al.
MODERN RHEUMATOLOGY (2019)
Dietary Interventions for Gout and Effect on Cardiovascular Risk Factors: A Systematic Review
Daisy Vedder et al.
NUTRIENTS (2019)
The effect of small dose of topiroxostat on serum uric acid in patients receiving hemodialysis
Yume Nagaoka et al.
HEMODIALYSIS INTERNATIONAL (2018)
Comparative effectiveness of allopurinol, febuxostat and benzbromarone on renal function in chronic kidney disease patients with hyperuricemia: a 13-year inception cohort study
Hsu-Wen Chou et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2018)
The influence of febuxostat on coronary artery endothelial dysfunction in patients with coronary artery disease: A phase 4 randomized, placebo-controlled, double-blind, crossover trial
Allison G. Hays et al.
AMERICAN HEART JOURNAL (2018)
Lesinurad: A Novel Agent for Management of Chronic Gout
Stacy L. Haber et al.
ANNALS OF PHARMACOTHERAPY (2018)
Xanthine oxidase inhibitors for prevention of cardiovascular events: a systematic review and meta-analysis of randomized controlled trials
Markus Bredemeier et al.
BMC CARDIOVASCULAR DISORDERS (2018)
Cardiovascular Risks of Probenecid Versus Allopurinol in Older Patients With Gout
Seoyoung C. Kim et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout
William B. White et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD study
Boris Waldman et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
International position paper on the appropriate use of uricosurics with the introduction of lesinurad
Tim L. Jansen et al.
CLINICAL RHEUMATOLOGY (2018)
Serum uric acid predicts incident metabolic syndrome in the elderly in an analysis of the Brisighella Heart Study
Arrigo Francesco Giuseppe Cicero et al.
SCIENTIFIC REPORTS (2018)
Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study
Roy Fleischmann et al.
RMD OPEN (2018)
Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta-analysis of randomized controlled trials
Yumo Zhao et al.
DIABETES OBESITY & METABOLISM (2018)
Effects of Allopurinol on Endothelial Function: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials
Arrigo F. G. Cicero et al.
DRUGS (2018)
Management of Acute and Recurrent Gout: A Clinical Practice Guideline From the American College of Physicians
Amir Qaseem et al.
ANNALS OF INTERNAL MEDICINE (2017)
Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study)
Thomas Bardin et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
2016 updated EULAR evidence-based recommendations for the management of gout
P. Richette et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Clinical efficacy and safety of topiroxostat in Japanese hyperuricemic patients with or without gout: a randomized, double-blinded, controlled phase 2b study
Tatsuo Hosoya et al.
CLINICAL RHEUMATOLOGY (2017)
Effect of Uric Acid-Lowering Agents on Endothelial Function A Randomized, Double-Blind, Placebo-Controlled Trial
Lea Borgi et al.
HYPERTENSION (2017)
The Pharmacodynamics, Pharmacokinetics, and Safety of Arhalofenate in Combination with Febuxostat When Treating Hyperuricemia Associated with Gout
Alexandra S. Steinberg et al.
JOURNAL OF RHEUMATOLOGY (2017)
Lesinurad Combined With Allopurinol: A Randomized, Double-Blind, Placebo-Controlled Study in Gout Patients With an Inadequate Response to Standard-of-Care Allopurinol (a US-Based Study)
Kenneth G. Saag et al.
ARTHRITIS & RHEUMATOLOGY (2017)
High serum uric acid is associated to poorly controlled blood pressure and higher arterial stiffness in hypertensive subjects
Arrigo F. G. Cicero et al.
EUROPEAN JOURNAL OF INTERNAL MEDICINE (2017)
Lesinurad for the treatment of hyperuricaemia in people with gout
Philip C. Robinson et al.
EXPERT OPINION ON PHARMACOTHERAPY (2017)
Current and future therapies for gout
Tristan Pascart et al.
EXPERT OPINION ON PHARMACOTHERAPY (2017)
Allopurinol as a therapeutic option in cardiovascular disease
Osita N. Okafor et al.
PHARMACOLOGY & THERAPEUTICS (2017)
Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6 month phase 3 clinical trial and extension study
Anne-Kathrin Tausche et al.
RHEUMATOLOGY (2017)
Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy adult male subjects
Zancong Shen et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2017)
Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout Findings of a Phase III Clinical Trial
Nicola Dalbeth et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Effects of uric acid-lowering therapy in patients with chronic kidney disease: A meta-analysis
Xiaole Su et al.
PLOS ONE (2017)
Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout
Philip K. Tan et al.
SCIENTIFIC REPORTS (2017)
An evidence-based review on urate-lowering treatments: implications for optimal treatment of chronic hyperuricemia
Marilisa Bove et al.
VASCULAR HEALTH AND RISK MANAGEMENT (2017)
Managing Gout Flares in the Elderly: Practical Considerations
Abhishek Abhishek
DRUGS & AGING (2017)
Metoprolol Increases Uric Acid and Risk of Gout in African Americans With Chronic Kidney Disease Attributed to Hypertension
Stephen P. Juraschek et al.
AMERICAN JOURNAL OF HYPERTENSION (2017)
Renoprotective effects of febuxostat compared with allopurinol in patients with hyperuricemia: A systematic review and meta-analysis
Sollip Kim et al.
KIDNEY RESEARCH AND CLINICAL PRACTICE (2017)
Evaluation of Pharmacokinetic Interactions Between Lesinurad, a New Selective Urate Reabsorption Inhibitor, and CYP Enzyme Substrates Sildenafil, Amlodipine, Tolbutamide, and Repaglinide
Michael Gillen et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2017)
Evaluation of Pharmacokinetic Interactions Between Lesinurad, a New Selective Urate Reabsorption Inhibitor, and Commonly Used Drugs for Gout Treatment
Zancong Shen et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2017)
Effects of topiroxostat and febuxostat on urinary albumin excretion and plasma xanthine oxidoreductase activity in dbidb mice
Takashi Nakamura et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2016)
A Randomized, Double-Blind, Active- and Placebo-Controlled Efficacy and Safety Study of Arhalofenate for Reducing Flare in Patients With Gout
Jeffrey Poiley et al.
ARTHRITIS & RHEUMATOLOGY (2016)
Treatment of hyperuricemia in gout: current therapeutic options, latest developments and clinical implications
Sebastian E. Sattui et al.
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE (2016)
Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney
Jeffrey Miner et al.
ARTHRITIS RESEARCH & THERAPY (2016)
A brief history of uric acid: From gout to cardiovascular risk factor
Francesco M. Galassi et al.
EUROPEAN JOURNAL OF INTERNAL MEDICINE (2015)
American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults
Sue Radcliff et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2015)
Pharmacogenetic considerations in the treatment of gout
Rebecca L. Roberts et al.
PHARMACOGENOMICS (2015)
Plasma uric acid concentrations are reduced by fenofibrate: A systematic review and meta-analysis of randomized placebo-controlled trials
Giuseppe Derosa et al.
PHARMACOLOGICAL RESEARCH (2015)
Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus
Yuliya Lytvyn et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2015)
SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria
Yukihiro Chino et al.
BIOPHARMACEUTICS & DRUG DISPOSITION (2014)
Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout
Tatsuo Hosoya et al.
CLINICAL AND EXPERIMENTAL NEPHROLOGY (2014)
Uricosuric drugs: the once and future therapy for hyperuricemia?
Mary H. Bach et al.
CURRENT OPINION IN RHEUMATOLOGY (2014)
As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout
A. -K. Tausche et al.
RHEUMATOLOGY INTERNATIONAL (2014)
Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout
Peter E. Lipsky et al.
ARTHRITIS RESEARCH & THERAPY (2014)
Blood pressure-lowering efficacy of monotherapy with thiazide diuretics for primary hypertension
Vijaya M. Musini et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2014)
Uric acid as a cross-over between rheumatology and cardiovascular disease
Claudio Borghi
CURRENT MEDICAL RESEARCH AND OPINION (2013)
Hyperuricaemia: more than just a cause of gout?
Niki Katsiki et al.
JOURNAL OF CARDIOVASCULAR MEDICINE (2013)
Genome-wide association analyses identify 18 new loci associated with serum urate concentrations
Anna Koettgen et al.
NATURE GENETICS (2013)
Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy
Herbert S. B. Baraf et al.
ARTHRITIS RESEARCH & THERAPY (2013)
Hypouricaemia and hyperuricosuria in familial renal glucosuria
Ines Aires et al.
CLINICAL KIDNEY JOURNAL (2013)
Prognostic Value of Uric Acid in Patients With ST-Elevated Myocardial Infarction Undergoing Primary Coronary Intervention
Mehmet G. Kaya et al.
AMERICAN JOURNAL OF CARDIOLOGY (2012)
Starting dose is a risk factor for allopurinol hypersensitivity syndrome: A proposed safe starting dose of allopurinol
Lisa K. Stamp et al.
ARTHRITIS AND RHEUMATISM (2012)
Uricases as Therapeutic Agents to Treat Refractory Gout: Current States and Future Directions
Xiaolan Yang et al.
DRUG DEVELOPMENT RESEARCH (2012)
Uric acid, hyperuricemia and vascular diseases
Ming Jin et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2012)
The interplay between diet, urate transporters and the risk for gout and hyperuricemia: current and future directions
Karina D. Torralba et al.
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (2012)
Meta-analysis identifies multiple loci associated with kidney function-related traits in east Asian populations
Yukinori Okada et al.
NATURE GENETICS (2012)
The genetics of hyperuricaemia and gout
Anthony M. Reginato et al.
NATURE REVIEWS RHEUMATOLOGY (2012)
Regulation of Uric Acid Excretion by the Kidney
Michael S. Lipkowitz
CURRENT RHEUMATOLOGY REPORTS (2012)
Using Allopurinol Above the Dose Based on Creatinine Clearance Is Effective and Safe in Patients With Chronic Gout, Including Those With Renal Impairment
Lisa K. Stamp et al.
ARTHRITIS AND RHEUMATISM (2011)
Febuxostat inhibition of endothelial-bound XO: Implications for targeting vascular ROS production
Umair Z. Malik et al.
FREE RADICAL BIOLOGY AND MEDICINE (2011)
Efficacy and Tolerability of Pegloticase for the Treatment of Chronic Gout in Patients Refractory to Conventional Treatment
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Interactions of urate transporter URAT1 in human kidney with uricosuric drugs
Ho Jung Shin et al.
NEPHROLOGY (2011)
Effect of Oral Vitamin C Supplementation on Serum Uric Acid: A Meta-Analysis of Randomized Controlled Trials
Stephen P. Juraschek et al.
ARTHRITIS CARE & RESEARCH (2011)
Effect of Allopurinol in Chronic Kidney Disease Progression and Cardiovascular Risk
Marian Goicoechea et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2010)
A 'complexity' of urate transporters
Alan F. Wright et al.
KIDNEY INTERNATIONAL (2010)
Febuxostat
Eliseo Pascual et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
Meta-Analysis of 28,141 Individuals Identifies Common Variants within Five New Loci That Influence Uric Acid Concentrations
Melanie Kolz et al.
PLOS GENETICS (2009)
A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout
Jeannie Chao et al.
Current Rheumatology Reports (2009)
Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT1) in hypertensive patients
Toshihiro Hamada et al.
AMERICAN JOURNAL OF HYPERTENSION (2008)
Probenecid, a gout remedy, inhibits pannexin 1 channels
William Silverman et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2008)
Optimizing therapy with allopurinol: Factors limiting hypouricemic efficacy
Yewon Chung et al.
AMERICAN JOURNAL OF THE MEDICAL SCIENCES (2008)
Effects of Febuxostat Versus Allopurinol and Placebo in Reducing Serum Urate in Subjects With Hyperuricemia and Gout: A 28-Week, Phase III, Randomized, Double-Blind, Parallel-Group Trial
H. Ralph Schumacher et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2008)
A benefit-risk assessment of benzbromarone in the treatment of gout - Was its withdrawal from the market in the best interest of patients?
Ming-Han H. Lee et al.
DRUG SAFETY (2008)
SLC2A9 - a fructose transporter identified as a novel uric acid transporter
MyPhuong T. Lei et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2008)
Involvement of uric acid transporters in alteration of serum uric acid level by angiotensin II receptor blockers
Masanobu Sato et al.
PHARMACEUTICAL RESEARCH (2008)
Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol
Richard O. Day et al.
CLINICAL PHARMACOKINETICS (2007)
Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level
YP Siu et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2006)
Febuxostat compared with allopurinol in patients with hyperuricemia and gout
MA Becker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol
SL Hung et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Urate transport via human PAH transporter hOAT1 and its gene structure
K Ichida et al.
KIDNEY INTERNATIONAL (2003)
Molecular identification of a renal urate-anion exchanger that regulates blood urate levels
A Enomoto et al.
NATURE (2002)
Loss of urate oxidase activity in hominoids and its evolutionary implications
M Oda et al.
MOLECULAR BIOLOGY AND EVOLUTION (2002)
Share Paper
